EUMA Pharma exists to end the chronic shortage of essential medicines in Ireland. We bring new, reliable supply lines into the country for the treatments patients depend on every day — and we do it with the rigour Ireland's regulators expect.
EUMA secures Irish authorisations for essential medicines and partners with qualified international manufacturers to ensure consistent supply to the Irish market. We are agile enough to respond quickly to emerging shortages, and committed to long-term partnerships rather than short-term commercial gain.
It is a patient missing a dose. A pharmacist on the phone instead of with a customer. A health service paying more for less. The impact lands in three places — and all of them matter.
When an essential medicine is not on the shelf, patients miss doses, switch to less suitable alternatives, or stop treatment altogether. For chronic conditions like depression, hypertension and diabetes, even short interruptions set treatment back and cause avoidable harm.
Shortages also create stress, travel and time costs — particularly for older patients, parents, and those managing multiple prescriptions.
Community pharmacists hold the system together when stock fails. They contact prescribers, borrow stock between pharmacies and counsel patients through unfamiliar substitutes — labour-intensive work that is largely unrecognised and unremunerated.
The cost is real: time away from clinical care, increased team workload, and growing professional fatigue across the network.
Shortages drive the system towards more expensive alternatives, exempt medicinal products and emergency procurement. They increase prescriber and pharmacist workload, and drive avoidable GP and hospital activity.
The European Court of Auditors describes shortages as a significant economic cost to national health systems — alongside the patient harm itself.
We do not run another report on the problem. We bring the missing medicines back to Irish patients — through Irish authorisations, qualified global partners, and the regulatory rigour the system demands.
An independent quarterly briefing for healthcare leaders, pharmacy groups, manufacturers and policy makers. Drawn from the HPRA register, IPU data and European supply-chain analysis — synthesised into a single, professionally formatted PDF.
Ireland's quarterly briefing on essential medicine supply. Drawn from HPRA, IPU and PGEU data.
We concentrate on solid oral dose medicines in therapeutic areas where shortages have become a chronic feature of the Irish healthcare system. Each authorisation we hold is matched to a real, persistent patient need.
Authorisations supporting psychiatric and neurological care in Irish primary and secondary settings.
Essential cardiac and hypertension therapies where continuity directly impacts patient outcomes.
Hormone, diabetes and metabolic medicines for chronic conditions requiring uninterrupted treatment.
Therapies for digestive conditions that have seen repeated and prolonged supply disruptions.
EUMA combines deep Irish regulatory knowledge with the manufacturing capability of carefully selected global partners. Every product in our portfolio is supported by five non-negotiable foundations.
Every product is sourced from a qualified manufacturing partner holding EU Good Manufacturing Practice certification.
A robust quality and vendor oversight programme governs every supplier relationship from qualification through routine supply.
Established Irish wholesale and pharmacy distribution channels deliver products to the patients who need them.
Full integration with HSE pricing and reimbursement processes, securing access through the Irish public system.
Full pharmacovigilance and regulatory compliance under Irish and EU requirements for every authorisation held.
A clear, repeatable pathway from identifying a chronic shortage on the Irish market to delivering reliable, compliant supply through Irish wholesale and pharmacy channels.
We monitor the HPRA register and HSE supply signals to identify essential medicines in chronic shortage on the Irish market.
We partner with EU GMP certified international manufacturers holding suitable dossiers, qualifying each through full vendor oversight.
EUMA secures and holds the Irish authorisation, integrating HSE pricing and reimbursement where applicable.
Products reach Irish patients through established wholesale and pharmacy channels, with full pharmacovigilance support.
We are agile enough to respond quickly to emerging shortages, and committed to long-term partnerships rather than short-term commercial gain.
One focus: securing reliable supply of the medicines that matter to Irish patients. No broader commercial agenda.
Structured to move quickly when new shortages emerge, with the regulatory and partnership capability to act within meaningful timeframes.
We build long-term relationships with manufacturers and wholesalers rather than chasing short-term commercial gain.
Deep working knowledge of HPRA, HSE pricing and Irish pharmacy distribution, applied to every authorisation we hold.
Pharmacists are spending more than six hours every week managing medicine shortages. Patients are waiting longer for treatments that should be on the shelf.
If you operate at any point on the medicines supply chain in Ireland, or are affected by ongoing shortages, we want to hear from you.
If you hold an EU dossier for a medicine relevant to the Irish market, EUMA can bring your product to Irish patients — quickly and to the standard the system demands.
Partner with us →EUMA works directly with established Irish wholesale and pharmacy distribution channels to deliver reliable supply through existing trade networks.
Trade enquiries →If you are a healthcare professional or patient affected by an ongoing shortage of an essential medicine in Ireland, we want to hear from you.
Report a shortage →Whether you are a manufacturer with an EU dossier, an Irish wholesaler or pharmacy group, or a healthcare professional affected by an ongoing shortage, we want to hear from you.